Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TVI-Biliary-1
- Development stage
- Unknown
- Lead developer
- TVAX Biomedical
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TVI-Biliary-1 is an autologous T-cell immunotherapy being developed by TVAX Biomedical for the treatment of biliary cancer. The therapy is based on the TVAX Immunotherapy platform, which employs a unique two-step approach: first, the patient is vaccinated with their own irradiated tumor cells combined with an adjuvant to prime the immune system; second, the resulting sensitized T-cells are harvested via leukapheresis, activated and expanded ex vivo using interleukin-2 (IL-2), and then re-infused into the patient. These 'educated' effector T-cells are designed to specifically target and eliminate the patient's tumor cells. TVI-Biliary-1 is currently in Phase 2 clinical development.
- Other names
- Biliary-1Biliary1Biliary 1
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on TVI-Biliary-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TVI-Biliary-1.